Technical Analysis for KIN - Kindred Biosciences, Inc.

Grade Last Price % Change Price Change
grade D 7.59 -1.43% -0.11
KIN closed down 1.43 percent on Friday, September 20, 2019, on approximately normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical KIN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Spinning Top Other 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.43%
Upper Bollinger Band Walk Strength -4.17%
Stochastic Reached Overbought Strength -6.30%
Upper Bollinger Band Walk Strength -6.30%
Inside Day Range Contraction -6.30%
Overbought Stochastic Strength -6.30%

Older signals for KIN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kindred Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for pets. The company is pursuing small molecules and biologics that are in various stages of development for a range of indications in dogs, cats, and horses. Its products include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs and horses; KIND-007, an inhibitor of Bruton's tyrosine kinase; and KIND-006, an agent for gastrointestinal diseases in cats. The company also has a portfolio of other drugs and biologics under development, which comprise anti-IgE antibody for allergic and immune-mediated diseases; canine analog of Enbrel for inflammatory and autoimmune diseases; canine analog of Orencia for immune-mediated diseases; and KIND-504, a cancer vaccine. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Medicine Biotechnology Health Biopharmaceutical Cancer Pain Immunology Immune System Inflammation Osteoarthritis Atopic Dermatitis Gastrointestinal Diseases Immune Mediated Diseases Inflammatory And Autoimmune Diseases Atopy Etanercept Flupirtine Immunoglobulin E
Is KIN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.11
52 Week Low 5.96
Average Volume 199,434
200-Day Moving Average 8.9859
50-Day Moving Average 7.2136
20-Day Moving Average 7.383
10-Day Moving Average 7.61
Average True Range 0.3927
ADX 20.3
+DI 31.412
-DI 17.9505
Chandelier Exit (Long, 3 ATRs ) 7.541900000000001
Chandelier Exit (Short, 3 ATRs ) 8.0881
Upper Bollinger Band 8.2482
Lower Bollinger Band 6.5178
Percent B (%b) 0.62
BandWidth 23.437627
MACD Line 0.151
MACD Signal Line 0.0909
MACD Histogram 0.0601
Fundamentals Value
Market Cap 211.28 Million
Num Shares 27.8 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -6.49
Price-to-Sales 0.00
Price-to-Book 2.41
PEG Ratio -0.15
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.03
Resistance 3 (R3) 8.04 7.92 7.95
Resistance 2 (R2) 7.92 7.81 7.91 7.93
Resistance 1 (R1) 7.75 7.74 7.69 7.74 7.90
Pivot Point 7.63 7.63 7.60 7.62 7.63
Support 1 (S1) 7.46 7.52 7.40 7.44 7.28
Support 2 (S2) 7.34 7.45 7.33 7.25
Support 3 (S3) 7.17 7.34 7.23
Support 4 (S4) 7.15